Seek Returns

ARGX vs. BIIB: argenx vs. Biogen Stock Comparison

How do argenx (ARGX) and Biogen (BIIB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Biogen (BIIB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Biogen (BIIB) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Biogen (BIIB)
Profile ItemARGXBIIB
Nameargenx SE American Depositary ReceiptBiogen Inc.
Country/RegionNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization58.31 billion USD36.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 18, 2017September 17, 1991
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
BIIB
GSPC
Loading price history…
argenx (ARGX) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Biogen (BIIB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Biogen (BIIB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Total Return (1Y)11.91%65.44%
Total Return (3Y, Annualized)25.68%4.62%
Total Return (5Y, Annualized)24.22%-0.96%

Risk Profile

Drawdown History

ARGX
BIIB
GSPC
Loading price history…
argenx (ARGX) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Biogen (BIIB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Volatility (1Y, Annualized)37.87%34.58%
Beta (5Y)0.450.08
Max Drawdown (5Y)-38.20%-64.35%
Avg. Volume (3M)359.84K1.05M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and BIIB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Sharpe Ratio (1Y)0.201.77
Sortino Ratio (1Y)0.312.77

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Biogen (BIIB) earns 1.87% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max
109.18%
Q3
6.23%
BIIB
1.87%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): ARGX does not report ROE, so it has no value marker; BIIB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max
18.05%
Q3
4.78%
BIIB
3.38%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both argenx (ARGX) at 36.27% and Biogen (BIIB) at 24.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max
83.12%
BIIB
24.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
ROE (TTM)--1.87%
ROA (TTM)--4.94%
Net Margin (TTM)31.73%3.38%
Operating Margin (TTM)36.27%24.12%
Gross Margin (TTM)59.84%75.77%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Biogen (BIIB) at 2.22% is closer to the peer norm — faster top-line expansion for ARGX.

Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both argenx (ARGX) at 53.13% and Biogen (BIIB) at -21.38% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Revenue Growth (YoY)89.64%2.22%
Revenue Growth (3Y CAGR)116.25%-0.94%
EPS Growth (YoY)53.13%-21.38%
EPS Growth (3Y CAGR)---25.04%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Biogen (BIIB) shows current ratio of 1.95 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BIIB
1.95
Min
0.10
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): ARGX does not report current ratio, so it has no value marker; BIIB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Biogen (BIIB) at 0.41 runs a more typical debt-to-equity mix.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max
1.42
Q3
0.65
BIIB
0.41
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Current Ratio (MRQ)--1.95
Debt / Equity (MRQ)0.010.41
Net Debt / EBITDA-2.701.97

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor Biogen (BIIB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor Biogen (BIIB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB
107.51
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Biogen (BIIB) at 3.57 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max
58.18
Q3
25.77
Median
7.30
BIIB
3.57
Q1
3.01
Min
0.01
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Biogen (BIIB) at 1.94 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max
13.53
Q3
6.54
Median
3.25
BIIB
1.94
Q1
1.69
Min
-5.59
Loading chart…
argenx (ARGX) vs. Biogen (BIIB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Biogen (BIIB)
MetricARGXBIIB
P/E Ratio (TTM)32.12107.51
P/S Ratio (TTM)9.863.57
P/B Ratio (MRQ)172.231.94
Free Cash Flow Yield (TTM)--2.20%